Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
Date:7/14/2008

>

Notes payable, less current portion - 119,000

Capital lease obligation, less current portion 22,000 30,000

Deferred license revenue - 4,000

Commitments and contingencies

STOCKHOLDERS' EQUITY:

Preferred stock - $.001 par value; authorized

5,000,000 shares; non-voting; nil shares

outstanding - -

Common stock - $.001 par value; authorized

325,000,000 shares; outstanding - 226,210,617

and 196,112,201, respectively 226,000 196,000

Additional paid-in-capital 246,205,000 224,453,000

Accumulated deficit (230,836,000) (207,660,000)

Total stockholders' equity 15,595,000 16,989,000

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $23,057,000 $22,997,000

-continued-

PEREGRINE PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2008

2008 2007 2006

REVENUES:

Contract manufacturing

revenue $5,897,000 $3,492,000 $3,005,000

License revenue 196,000 216,000 188,000

Total revenues 6,093,000 3,708,000 3,193,000

COSTS AND EXPENSES:

Cost of contract

manufacturing 4,804,000 3,296,000 3,297,000

Research and development 18,279,000 15,876,000 12,415,000

Selling, general and

administrative 7,150,000 6,446,000 6,564,000

Total costs and

expenses 30,233,000 25,618,000 22,276,000

LOSS FROM OPERATIONS (24,140,000) (21,910,000) (19,08
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
2. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
3. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
4. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
7. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
11. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... (PRWEB) July 26, 2014 Canada ... key market data on the Canada Endoscopy Visualization ... of US dollars, volume (in units) and average ... High-End Endoscopy Visualization Systems, Mid-Range Endoscopy Visualization Systems ... Report at http://www.marketresearchreports.biz/analysis/213254 . , The report ...
(Date:7/25/2014)... 2014 "Ischemic Stroke and Cerebral ... data on the Ischemic Stroke and Cerebral Stroke ... and data relating to the clinical trials on ... global Ischemic Stroke Research Report 2014 at: ... the trial numbers and their recruitment status as ...
(Date:7/25/2014)... , July 25, 2014 Amgen (NASDAQ: ... Directors today declared a $0.61 per share dividend for ... paid on Sept. 5, 2014, to all stockholders of ... 14, 2014.  About Amgen Amgen is ... suffering from serious illnesses by discovering, developing, manufacturing and ...
(Date:7/25/2014)... -- Trillions of bacteria live in each person,s digestive ... digest food and stave off harmful infections, but their ... To help shed light on the role of these ... professor Eric Alm recently tracked fluctuations in the bacterial ... The findings, described in the July 25 issue of ...
Breaking Biology Technology:Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3
... sensors seem like something from a futuristic movie. ... headquartered in Neenah, Wis., is making those futuristic ... a leading manufacturer of fingerprint sensors. , ,Plexus ... design and integration services for AuthenTec's TruePrint technology-based ...
... in alternative energy , ,Madison, WI - WE ... with two developers that will build three wind farms ... Wisconsin by 400%. , ,Under the agreement, the two ... Energy, LLC, based in Chicago, will provide their entire ...
... software makes direct mail an attractive option , ... view direct mailing as a hit-or-miss attempt to reach ... 7.32c is a software system designed to give organizations ... make this form of marketing a more affordable option ...
Cached Biology Technology:Plexus Partnering with AuthenTec 2WE Energies Is Not Letting Wind Power Blow Away 2Reaching Them Through the Mail 2
(Date:7/27/2014)... vitro study has revealed that nicotine and cotinine, a ... by a certain carcinogen in smoke. , The carcinogen ... tobacco leaves and ultimately ends up in the tobacco ... and liver, where it is activated by a variety ... mice has revealed that nicotine can partially interfere with ...
(Date:7/27/2014)... asteroid strike that wiped them out if it had ... say. , A fresh study using up-to-date fossil records ... a new narrative of the prehistoric creatures, demise, some ... the few million years before a 10km-wide asteroid struck ... This included extensive volcanic activity, changing sea levels and ...
(Date:7/27/2014)... to date, researchers from the U.K. provide national, regional, ... virus (HCV). Findings published in Hepatology, a journal of ... indicate that genotype 1 is the most prevalent worldwide, ... reside in East Asia. Genotype 3, at just over ... by genotypes 2, 4, 6, and 5. , ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Dinosaurs fell victim to perfect storm of events, study shows 2Hepatitis C virus genotype 1 is most prevalent worldwide 2
... The National Academy of Sciences today elected Dr. David ... and a Howard Hughes Medical Institute investigator, to membership, ... scientist. Three other Texans, all from UT Austin, ... associates who were elected today to the NAS. They ...
... Ted Nordhaus and Michael Shellenberger, whose critiques of the ... and goals, have won the 2008 Green Book Award ... , Nordhaus and Shellenberger won for their 2007 ... the Politics of Possibility. An expansion of their widely ...
... resulting in ... and better user experience, WALL, N.J., April 28 ... in finger-based biometric,identification and wireless public safety solutions, today ... Trademark Office issued US patent,No. 7,359,553 covering BIO-key,s image ...
Cached Biology News:UT Southwestern's Mangelsdorf elected to National Academy of Sciences 2UT Southwestern's Mangelsdorf elected to National Academy of Sciences 3Stevens' Center for Science Writings honors environmental critics with Green Book Award, April 30 2BIO-key(R) Granted Image Identification System Patent for Award Winning Biometric Technology 2BIO-key(R) Granted Image Identification System Patent for Award Winning Biometric Technology 3